Aurora's CBD Lozenge Partnership: Here's Where To Find The New Product

Zinger Key Points
  • Aurora Cannabis and Vectura Fertin Pharma announced the launch of a newly developed Luo CBD lozenge in Canada.
  • Through Aurora's patient platform, Cogent will gain access to patient feedback on the CBD lozenge.

Canadian medical cannabis company Aurora Cannabis Inc. ACB ACB and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, announced on Monday the launch of the newly developed Luo CBD lozenge.

What Happened

The product was developed by Vectura Fertin Pharma, and represents the company's first medical cannabis CBD lozenge to be introduced in Canada.

The move follows the announced commercial collaboration between Vectura Fertin Pharma's subsidiary Cogent International and the Edmonton, Alberta-based company to leverage Aurora’s Canadian medical cannabis patient platform.

Cogent manufactures, packages and labels the CBG lozenge, a novel dissolvable format and is easy to dose.

Read Also: Aurora Cannabis Shares Jump On Q1 FY25 Earnings, Global Medical Marijuana Yields Record Revenue Of $343M

  • Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.

Why It Matters

Through Aurora’s patient platform, Cogent will gain access to patient feedback on the CBD lozenge, which will be used to validate the product proposition and build real-world patient data to inform future products.

“As the leading provider of medical cannabis in Canada, the launch of the newly developed Luo CBD lozenge on our platform is a significant and exciting milestone at the beginning of our strategic collaboration with Vectura Fertin Pharma," said Aurora CEO Miguel Martin. "We are committed to bringing innovative solutions to patients and this launch reinforces our position at the forefront of Canada’s medical cannabis industry.”

What's Next

The two companies are open to exploring opportunities regarding the potential commercialization of other Vectura Fertin Pharma medical cannabis products in Canada.

ACB Price Action

Aurora's shares traded 2.96% higher at $5.57 per share during the pre-market session on Monday morning.

Read Next:

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisNewsRetail SalesCanada CannabisCBDCCCMiguel MartinVectura Fertin Pharma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.